Jefferies Financial Group set a $220.00 price objective on Amgen (NASDAQ:AMGN) in a research report sent to investors on Thursday morning. The brokerage currently has a buy rating on the medical research company’s stock.

Several other research firms have also recently weighed in on AMGN. Oppenheimer reissued a buy rating and set a $224.00 price objective on shares of Amgen in a report on Tuesday, August 28th. Wells Fargo & Co reissued a neutral rating and set a $197.00 price objective on shares of Amgen in a report on Wednesday, August 29th. Morgan Stanley boosted their price objective on shares of Amgen from $200.00 to $210.00 and gave the company a buy rating in a report on Friday, July 13th. BidaskClub raised shares of Amgen from a buy rating to a strong-buy rating in a report on Wednesday, July 11th. Finally, Piper Jaffray Companies boosted their price objective on shares of Amgen from $190.00 to $210.00 and gave the company an overweight rating in a report on Thursday, July 26th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, twelve have given a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of $202.76.

Amgen stock traded up $0.86 during trading hours on Thursday, hitting $197.01. The stock had a trading volume of 33,647 shares, compared to its average volume of 1,819,469. The company has a debt-to-equity ratio of 2.03, a quick ratio of 3.12 and a current ratio of 3.39. The stock has a market capitalization of $128.00 billion, a PE ratio of 15.59, a price-to-earnings-growth ratio of 1.93 and a beta of 1.39. Amgen has a 12-month low of $163.31 and a 12-month high of $201.23.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, July 26th. The medical research company reported $3.83 earnings per share for the quarter, beating the consensus estimate of $3.52 by $0.31. Amgen had a net margin of 10.19% and a return on equity of 43.18%. The firm had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $5.73 billion. During the same period in the previous year, the company earned $3.27 earnings per share. The firm’s quarterly revenue was up 4.3% on a year-over-year basis. equities research analysts forecast that Amgen will post 13.95 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 7th. Investors of record on Friday, August 17th will be given a dividend of $1.32 per share. The ex-dividend date of this dividend is Thursday, August 16th. This represents a $5.28 annualized dividend and a yield of 2.68%. Amgen’s dividend payout ratio (DPR) is 41.97%.

In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $184.27, for a total transaction of $281,011.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.19% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Pillar Pacific Capital Management LLC boosted its position in shares of Amgen by 0.5% in the second quarter. Pillar Pacific Capital Management LLC now owns 56,671 shares of the medical research company’s stock worth $10,461,000 after purchasing an additional 254 shares during the period. Fairfield Bush & CO. boosted its position in shares of Amgen by 0.8% in the second quarter. Fairfield Bush & CO. now owns 33,934 shares of the medical research company’s stock worth $6,264,000 after purchasing an additional 260 shares during the period. Advisors Capital Management LLC boosted its position in shares of Amgen by 5.8% in the second quarter. Advisors Capital Management LLC now owns 4,737 shares of the medical research company’s stock worth $874,000 after purchasing an additional 261 shares during the period. Highland Capital Management LLC boosted its position in shares of Amgen by 1.0% in the second quarter. Highland Capital Management LLC now owns 27,457 shares of the medical research company’s stock worth $5,068,000 after purchasing an additional 262 shares during the period. Finally, Mutual Advisors LLC boosted its position in shares of Amgen by 5.8% in the second quarter. Mutual Advisors LLC now owns 4,814 shares of the medical research company’s stock worth $889,000 after purchasing an additional 265 shares during the period. Institutional investors own 77.23% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Featured Story: Marijuana Stocks

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.